Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Identification of prognostic factors and surgical indications for metastatic gastric cancer

Authors: Yasuhiko Mohri, Koji Tanaka, Masaki Ohi, Susumu Saigusa, Hiromi Yasuda, Yuji Toiyama, Toshimitu Araki, Yasuhiro Inoue, Masato Kusunoki

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The treatment of metastatic gastric cancer is not uniform, and the prognostic factors and indications for surgery are currently unclear. This retrospective study aimed to identify the prognostic factors and clinical indications for surgery in patients with metastatic gastric cancer.

Methods

A total of 123 consecutive patients with gastric cancer and synchronous distant metastasis treated between January 1999 and December 2011 were reviewed. Patient, tumor, laboratory, surgical, and chemotherapy factors were analyzed, with overall survival as the endpoint. Univariate analyses were performed using the log-rank test, multivariate analyses were performed using the Cox proportional hazards model, and Kaplan-Meier curves were used to estimate survival. Significance was set at p < 0.05.

Results

The median overall survival time was 13.1 months. Ninety-eight patients received chemotherapy. Twenty-eight patients underwent gastrectomy with metastasectomy and 55 underwent gastrectomy without metastasectomy. The median overall survival time for patients who underwent gastrectomy with metastasectomy, gastrectomy without metastasectomy, and no surgical intervention was 21.9 months, 12.5 months, and 7.2 months, respectively (p < 0.001). Multivariate analysis identified gastrectomy with or without metastasectomy, performance status (PS) ≥3, neutrophil-to-lymphocyte ratio (NLR) >3.1, and carbohydrate antigen 19–9 (CA19-9) level >37 U/mL as predictors of poor survival. NLR and CA19-9 level were also independent prognostic factors in the group of patients who underwent surgery.

Conclusions

High pretreatment NLR, CA19-9 level, and PS are predictors of poor prognosis in patients with metastatic gastric cancer. In selected patients, gastrectomy can be performed safely, and may be associated with longer survival.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995, 71: 587-591. 10.1038/bjc.1995.114.CrossRefPubMedPubMedCentral
3.
Wohrer SS, Raderer M, Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004, 15: 1585-1595. 10.1093/annonc/mdh422.CrossRefPubMed
4.
Ajani JA, Bentrem DJ, Besh G, D’Amico TA, Das P, Denilinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, MaMillan NR, et al: National Comprehensive Cancer Network (NCCN) clinical practice guideline in oncology: gastric cancer (version 2 2013). Fort Washington: NCCN, http://​www.​nccn.​org/​professionals/​physician_​gls/​f_​guidelines.​asp,
5.
Medina-Franco H, Contreras-Saldivar A, Ramos-De La Medina A, Palacios-Sanchez P, Cortés-González R, Uqarte JA: Surgery for stage IV gastric cancer. Am J Surg. 2004, 187: 543-546. 10.1016/j.amjsurg.2003.12.045.CrossRefPubMed
6.
Ouchi K, Sugawara T, Ono H, Fujiya T, Kamiyama Y, Kakugawa Y, Mikuni J, Yamanami H: Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol. 1998, 69: 41-44. 10.1002/(SICI)1096-9098(199809)69:1<41::AID-JSO8>3.0.CO;2-K.CrossRefPubMed
7.
Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group: Value of palliative resection in gastric cancer. Br J Surg. 2002, 89: 1438-1443. 10.1046/j.1365-2168.2002.02220.x.CrossRefPubMed
8.
Gold JS, Jaques DP, Bentrem DJ, Shah MA, Tang LH, Brennan MF, Coit DG: Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent. Ann Surg Oncol. 2007, 14: 365-372. 10.1245/s10434-006-9059-z.CrossRefPubMed
9.
Martin RC, Jaques DP, Brennan MF, Karpeh M: Achieving R0 resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection?. J Am Coll Surg. 2002, 194: 568-577. 10.1016/S1072-7515(02)01116-X.CrossRefPubMed
10.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleiq WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006, 24: 2903-2909. 10.1200/JCO.2005.05.0245.CrossRefPubMed
11.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPILITS trial): a phase III trial. Lancet Oncol. 2008, 9: 215-221. 10.1016/S1470-2045(08)70035-4.CrossRefPubMed
12.
Japanese Research Society for Gastric Cancer: Japanese classification of gastric carcinoma. 1995, Tokyo: Kanehara, 1
13.
MacCarter MD, Fong Y: Role for surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol. 2001, 8: 38-43. 10.1007/s10434-001-0038-0.CrossRef
14.
Saidi RF, ReMine SG, Dudrick PS, Hanna NN: Is there a role for non-curative gastrectomy in patients with stage IV gastric cancer?. World J Surg. 2006, 30: 21-27. 10.1007/s00268-005-0129-3.CrossRefPubMed
15.
Pollock RE, Roth JA: Cancer-induced immunosupression: implication for therapy?. Semin Surg Oncol. 1989, 5: 414-419. 10.1002/ssu.2980050607.CrossRefPubMed
16.
Sun J, Song Y, Wang Z, Chen X, Gao P, Xu Y, Zhou B, Xu H: Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2013, 13: 577-10.1186/1471-2407-13-577.CrossRefPubMedPubMedCentral
17.
Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL: Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis. Cancer. 2013, 119: 1636-1642. 10.1002/cncr.27927.CrossRefPubMed
18.
Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyer J, O’Brien M, Bensted J: The prognostic value of serum and immunohistochemical tumor markers in advanced gastric cancer. Eur J Cancer. 1996, 32: 63-68.CrossRef
19.
Koprowski H, Stepleski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979, 5: 957-972. 10.1007/BF01542654.CrossRefPubMed
20.
Sakamoto J, Furukawa K, Crodon-Cardo C, Yin BW, Rettig WJ, Oettgen HF, Old LJ, Lioyd KO: Expression of Lewiusa, Lewisb, Lewisy, sialyl Lewisx, blood group antigens in human gastric carcinoma and normal cancer tisuue. Cancer Res. 1989, 49: 745-752.PubMed
21.
Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, Kasahara M, Mochizuki F, Kasakura Y, Yamagata M: Evaluation of serum CEA and CA 19–9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000, 2: 177-186.CrossRef
22.
Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T: The prognostic value of preoperative serum levels of CEA and CA 19–9 in patients with gastric cancer. Am J Gastroenterol. 1996, 91: 49-53.PubMed
23.
Miner TJ, Jaques DP, Karpeh MS, Brennan MF: Defining palliative surgery in patients receiving noncurative resections for gastric cancer. J Am Coll Surg. 2004, 198: 1013-1021. 10.1016/j.jamcollsurg.2004.02.007.CrossRefPubMed
24.
Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park do J, Kim JH, Kim HH, Lee JS: Survival benefit of gastrectomy ± metastatectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer. 2011, 14: 130-138. 10.1007/s10120-011-0015-7.CrossRefPubMed
25.
Kulig P, Sierzega M, Kowalczk T, Kolodziejczk P, Kuliq J: Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012, 38: 490-496. 10.1016/j.ejso.2012.01.013.CrossRefPubMed
26.
Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008, 19: 1146-1153. 10.1093/annonc/mdn026.CrossRefPubMed
27.
Fujitani K, Yang HK, Kurokawa Y, Park do J, Tsujinaka T, Park BJ, Fukuda H, Noh SH, Boku N, Bang YJ, Sasako M, Lee JI, Gastric Cancer Surgical Study Group of Japan Clinical Oncology Group; Korean Gastric Cancer Association: Randomized controlled trial comparing gastectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan clinical oncology group study JCOG 0705 and Korea gastric cancer association study KGCA01. Jpn J Clin Oncol. 2008, 38: 504-506. 10.1093/jjco/hyn058.CrossRefPubMed
28.
Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwohg KF, Quezado M, Goldspiel BR, Venkatesan A, Berger A, Walker M, Toomey MA, Steinberg SM, Giaccone G, Rosenberg SA, Avital I: The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastatectomy plus systemic therapy versus systemic therapy alone. BMC Trials. 2009, 10: 121-10.1186/1745-6215-10-121.CrossRef
Metadata
Title
Identification of prognostic factors and surgical indications for metastatic gastric cancer
Authors
Yasuhiko Mohri
Koji Tanaka
Masaki Ohi
Susumu Saigusa
Hiromi Yasuda
Yuji Toiyama
Toshimitu Araki
Yasuhiro Inoue
Masato Kusunoki
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-409

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs

Research article

Smoking increases rectal cancer risk to the same extent in women as in men: results from a Norwegian cohort study

Research article

Racial differences in mantle cell lymphoma in the United States

Research article

Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades

Research article

Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

Research article

Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits